- Home
- EMF vs LRMR Comparison
EMF vs LRMR Comparison
Compare EMF & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EMF | LRMR |
|---|---|---|
| Founded | 1987 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.1M | 280.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EMF | LRMR |
|---|---|---|
| Price | $20.17 | $3.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 29.3K | ★ 1.2M |
| Earning Date | 01-01-0001 | 03-23-2026 |
| Dividend Yield | ★ 6.16% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.58 | $1.61 |
| 52 Week High | $12.67 | $5.37 |
Technical Indicators
Market Signals| Indicator | EMF | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 71.11 | 41.74 |
| Support Level | $19.29 | $3.06 |
| Resistance Level | $20.02 | $3.48 |
| Average True Range (ATR) | 0.32 | 0.21 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 79.03 | 20.00 |
Price Performance
Historical ComparisonAbout EMF Templeton Emerging Markets Fund
Templeton Emerging Markets Fund is a closed-end management investment company that seeks long-term capital appreciation by investing mainly in emerging country equity securities under normal market conditions. It invests across various sectors, including Pharmaceuticals, Beverages, Broadline Retail, Metals & Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, Insurance, Entertainment, and others.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.